UroGen Pharma Ltd. (NASDAQ:URGN)
Industry: Healthcare

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.

Current Quote*
Last: $46.830
Change: -0.740
Book: $6.112
Volume: 76,471

As Of: 11/14 14:48 ET
*Quotes delayed by 20min.

Graphs for URGN


3 Month Graph


6 Month Graph


1 Year Graph